Hans Deckmyn
Hans Deckmyn
Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk, Belgium
Verified email at - Homepage
Cited by
Cited by
The metabolism of phosphoinositide-derived messenger molecules
PW Majerus, TM Connolly, H Deckmyn, TS Ross, TE Bross, H Ishii, ...
Science 234 (4783), 1519-1526, 1986
Platelets at work in primary hemostasis
K Broos, HB Feys, SF De Meyer, K Vanhoorelbeke, H Deckmyn
Blood reviews 25 (4), 155-167, 2011
Platelet actuation
D Blockmans, H Deckmyn, J Vermylen
Blood reviews 9 (3), 143-156, 1995
Neutrophil extracellular traps in ischemic stroke thrombi
E Laridan, F Denorme, L Desender, O Francois, T Andersson, H Deckmyn, ...
Annals of neurology 82 (2), 223-232, 2017
Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood
PRM Siljander, ICA Munnix, PA Smethurst, H Deckmyn, T Lindhout, ...
Blood 103 (4), 1333-1341, 2004
The hemostatic system
JM Stassen, J Arnout, H Deckmyn
Current medicinal chemistry 11 (17), 2245-2260, 2004
Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients
Y Vanrenterghem, T Lerut, L Roels, J Gruwez, P Michielsen, ...
The Lancet 325 (8436), 999-1002, 1985
MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
K Peerlinck, I De Lepeleire, M Goldberg, D Farrell, J Barrett, E Hand, ...
Circulation 88 (4), 1512-1517, 1993
Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.
H Matsuno, JM Stassen, J Vermylen, H Deckmyn
Circulation 90 (5), 2203-2206, 1994
Platelet adhesion to collagen
BP Nuyttens, T Thijs, H Deckmyn, K Broos
Thrombosis research 127, S26-S29, 2011
von Willebrand factor to the rescue
SF De Meyer, H Deckmyn, K Vanhoorelbeke
Blood, The Journal of the American Society of Hematology 113 (21), 5049-5057, 2009
Matrix-specific suppression of integrin activation in shear stress signaling
AW Orr, MH Ginsberg, SJ Shattil, H Deckmyn, MA Schwartz
Molecular biology of the cell 17 (11), 4686-4697, 2006
Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance
S Staessens, F Denorme, O Francois, L Desender, T Dewaele, ...
Haematologica 105 (2), 498, 2020
Deficiency of von Willebrand factor protects mice from ischemic stroke
C Kleinschnitz, SF De Meyer, T Schwarz, M Austinat, K Vanhoorelbeke, ...
Blood, The Journal of the American Society of Hematology 113 (15), 3600-3603, 2009
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis
HB Feys, MT Canciani, F Peyvandi, H Deckmyn, K Vanhoorelbeke, ...
British journal of haematology 138 (4), 534-540, 2007
Dipyridamole inhibits platelet aggregation in whole blood
P Gresele, C Zoja, H Deckmyn, J Arnout, J Vermylen, M Verstraete
Thrombosis and haemostasis 50 (08), 852-856, 1983
A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2
G Defreyn, H Deckmyn, J Vermylen
Thrombosis research 26 (6), 389-400, 1982
Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men
JS Barrett, G Murphy, K Peerlinck, ID Lepeleire, RJ Gould, D Panebianco, ...
Clinical Pharmacology & Therapeutics 56 (4), 377-388, 1994
Shielding of the A1 domain by the D′ D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V
H Ulrichts, M Udvardy, PJ Lenting, I Pareyn, N Vandeputte, ...
Journal of Biological Chemistry 281 (8), 4699-4707, 2006
ADAMTS13-mediated thrombolysis of t-PA–resistant occlusions in ischemic stroke in mice
F Denorme, F Langhauser, L Desender, A Vandenbulcke, H Rottensteiner, ...
Blood, The Journal of the American Society of Hematology 127 (19), 2337-2345, 2016
The system can't perform the operation now. Try again later.
Articles 1–20